NeuroTimone Facility (PFNT)

The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.

News

  1. 2019 Retrospective: D. Figarella-Branger from the GlioME team was involved in 5 reference articles on pediatric brain tumours

    Thanks to her expertise in the diagnosis of central nervous system tumours arising in children and young adults, Dominique Figarella-Branger from the GlioME team (Team 8) was involved last year in 5 articles published in high-impact factor journals (>18). These articles are becoming references in this field:

    - The molecular landscape of ETMR at diagnosis and relapse. Nature. 2019 Dec;576(7786):274-280. PMID: 31802000

    - EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. Lancet Oncol. 2019 Dec;20(12):e715-e728.PMID: 31797797

  2. "Alzheimer's disease: a year of hope" (La Marseillaise - January 2020)
  3. New publication of the NeuroCyto team

    First work of 2020 work is out for the NeuroCyto team! A collaboration with Matt Rasband’s lab in Nature Communications. This is a significant paper for the axon initial segment field: Matt’s lab used BioID of key AIS proteins for mapping AIS components. Dozens of new candidates for future studies! We performed super-resolution microscopy of several of the newly identified AIS components. IN particular, we showed that Mical3, a protein linking microtubules and actin, forms clusters along the AIS that are not periodically organized along the actin/spectrin scaffold.

  4. France Culture highlights the recent article from the NeuroCyto team
  5. Just out from the NeuroCyto team: the ultrastructure of actin rings revealed
  6. New publication from the GlioME Team and the national POLA network (dedicated to high grade oligodendroglioma) pointing at CDKN2A homozygous deletion as a strong adverse prognostic factor in diffuse malignant IDH-mutant gliomas.

    In a large cohort of 911 high-grade IDH-mutant gliomas from the French national POLA network, we investigated the prognostic value of the CDKN2A gene homozygous deletion as well as WHO grading criteria (mitoses, microvascular proliferation, and necrosis).

    We showed that:
    - CDKN2A homozygous deletion characterizes diffuse malignant IDH-mutant gliomas with worst outcome.

    - Microvascular proliferation stratifies IDH-mutant gliomas lacking CDKN2A homozygous deletion.

  7. INP & Vect-Horus first day off in Black Stone pub

    On thursday december the 12th, most of INP and Vect-Horus members got together and spent a day in the Black Stone pub, Marseille, to celebrate the fact that nearly two years after its creation, the Institute of NeuroPhysiopathology is finally located on Tmone Campus.

  8. Michel KHRESTCHATISKY invited to the third edition of “Translational neuroscience Day: challenges and opportunities” co-organized by DHUNE and NeurATRIS

Pages

INP in numbers

  • 126 members
  • 44 researchers
  • 48 research assistants
  • 12 post-docs
  • 11 PhD

 

New publication from the GlioME Team and the national POLA network (dedicated to high grade oligodendroglioma) pointing at CDKN2A homozygous deletion as a strong adverse prognostic factor in diffuse malignant IDH-mutant gliomas.

In a large cohort of 911 high-grade IDH-mutant gliomas from the French national POLA network, we investigated the prognostic value of the CDKN2A gene homozygous deletion as well as WHO grading criteria (mitoses, microvascular proliferation, and necrosis).

We showed that:
- CDKN2A homozygous deletion characterizes diffuse malignant IDH-mutant gliomas with worst outcome.

- Microvascular proliferation stratifies IDH-mutant gliomas lacking CDKN2A homozygous deletion.

English

Michel KHRESTCHATISKY invited to the third edition of “Translational neuroscience Day: challenges and opportunities” co-organized by DHUNE and NeurATRIS

Michel KHRESTCHATISKY, Director of the UMR7051 Institute of Neurophysiopathology at Aix-Marseille University / CNRS and co-founder of VECT-HORUS was invited at the third edition of Translational neuroscience Day: challenges and opportunities” co-organized by DHUNE and NeurATRIS and hosted by BioFIT on December 10, 2019 (https://www.biofit-event.com/translational-neuroscience).

Undefined

New publication for the Neuro-inflammation and Multiple Sclerosis team (INP team 5) in Cytokine about the immunomonitoring of infliximab biotherapies

In this paper, Daniel Bertin evaluated the immunological follow-up of patients suffering from chronic inflammatory diseases and receiving anti-TNF biotherapy. Three commercial ELISA assays for monitoring soluble through levels of infliximab and anti-infliximab antibodies in serum showed a good global correlation of results. However, some quantitative discrepancies could change clinical decision. As a consequence, Daniel Bertin recommended to keep the same kit to perform a longitudinal follow-up of patients.

Undefined

Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response" .

Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, in the Insitute of NeuroPhysiopathology, UMR CNRS 7051, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response".

Subsequently she was interviewed by :
France 3  (JT 19/20 PACA diffusion du 15/11: 7'09 à 9'45) ; 
Provence Azur (18/11/2019) ;
20 Minutes Marseille (18/11/2019)
- La Provence

 

Undefined

GlioME team in collaboration with INT (Institute of Neurosciences Timone) published a new study in Journal of Neuroinflammation on the effect of Bevacizumab on glioblastoma-bearing mice, using 2-photon imaging

Our data show that VEGF blockade leads to an increased recruitment of monocytes and to an adjustment of dendritic cell subsets’ profiles, differing in their ability to induce an adaptive immune response. Altogether, they provide important new insights into the effects of Bevacizumab at the cellular level and into the spatio-temporal evolution of intra-tumoral innate immune cell densities.

Undefined

Partners